IBS Personalized Diet vs. Low FODMAP Diet Randomized Control Trial

Irritable bowel syndrome (IBS) is considered the most common gastrointestinal disorder in humans, with an estimated global prevalence of 11%-20% of all humans. Alterations in the gut microbiome are at the center of IBS, and microbiome-induced volatile metabolites in response to dietary exposures is believed to drive a downstream impact on susceptible hosts, thereby driving the disease. However, the characteristics and functions of these metabolites remain unknown to date. This placebo-controlled interventional study examines person-specific small molecules and bacteria driving IBS and their downstream effects on the human gut epithelium.

Inclusion Criteria: * Male and Female * Age - 18-70 Exclusion Criteria: * Consumption of antibiotics 2 months prior to enrolment. * Consumption of probiotic supplements 2 weeks prior to enrolment. * Type 1 or type 2 diabetes diagnosis. * Pregnancy, fertility treatments, breastfeeding 3 months prior to the first day of the study. * Chronic disease - to the discretion of the study medical team. * Cancer and recent anticancer treatment. * Immunosuppression. * Psychiatric disorders - to the discretion of the medical team * History of gastrointestinal surgeries - to the discretion of the medical team * Inflammatory bowel diseases or gastrointestinal disorders - to the discretion of the medical team * Unstable doses of medications in the past 2 months * Alcohol or substance abuse.